Company profile for Pharvaris

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule brad...
Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Switzerland
Address
Address
Grafenauweg 8 CH-6300 Zug
Telephone
Telephone
+1-646-942-5630
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/03/3198720/0/en/Pharvaris-Announces-Positive-Topline-Data-from-RAPIDe-3-Pivotal-Study-Confirming-Potential-of-Deucrictibant-for-On-Demand-Treatment-of-HAE-Attacks.html

GLOBENEWSWIRE
03 Dec 2025

https://www.globenewswire.com/news-release/2025/10/23/3171859/0/en/Pharvaris-to-Present-Clinical-Data-at-the-ACAAI-2025-Annual-Scientific-Meeting.html

GLOBENEWSWIRE
23 Oct 2025

https://www.globenewswire.com/news-release/2025/08/12/3132128/0/en/Pharvaris-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
12 Aug 2025

https://www.globenewswire.com/news-release/2025/07/24/3121449/0/en/Pharvaris-Announces-Closing-of-201-2-Million-Upsized-Public-Offering-of-Ordinary-Shares-and-Pre-Funded-Warrants-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shar.html

GLOBENEWSWIRE
24 Jul 2025

https://www.globenewswire.com/news-release/2025/07/23/3119954/0/en/Pharvaris-Announces-Pricing-of-Upsized-175-Million-Public-Offering-of-Ordinary-Shares-and-Pre-Funded-Warrants.html

GLOBENEWSWIRE
22 Jul 2025

https://www.globenewswire.com/news-release/2025/07/22/3119831/0/en/Pharvaris-Announces-Proposed-Public-Offering-of-Ordinary-Shares.html

GLOBENEWSWIRE
22 Jul 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty